Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any gender.
• People who have been formally diagnosed with multiple myeloma based on established international diagnostic guidelines.
• People who have already been through at least 3 separate courses of treatment for multiple myeloma, or whose myeloma has stopped responding to two specific types of standard treatments (an IMiD and a PI, as defined by international guidelines).
• People who still have measurable signs of the disease at the time of screening, according to international myeloma guidelines.
• People whose general physical functioning falls within a certain range on a standard medical scale (rated 0 to 2 out of 4, meaning independent or only mildly limited in daily activities).
• People whose heart, lungs, liver, kidneys, and blood counts meet certain minimum health thresholds set out in the trial protocol (confirm with trial site for specific values).
• Women who could become pregnant must have a negative pregnancy test and agree to use effective contraception throughout the trial.
• People who have read and understood the trial's consent form and are willing to sign it — those who cannot sign due to being unable to read may do so with an impartial witness present.
• People who are willing and able to follow all of the trial's procedures, schedules, and requirements throughout the study.

Who may not be able to join:

• People who have previously received any CAR-T cell therapy, or any treatment specifically targeting a protein called BCMA.
• People who have a current or past history of multiple myeloma affecting the brain or spinal cord, or who show signs of this.
• People who have had a stroke or seizure within the 6 months before signing the consent form.
• People with an active, uncontrolled infection, including uncontrolled bacterial, fungal, hepatitis B, hepatitis C, or HIV infection.
• People with significant heart disease or severe lung disease (confirm with trial site for specific definitions).
• People who have recently received a bone marrow transplant from a donor and are still experiencing transplant-related immune complications or are on immune-suppressing medication for this reason.
• People who are pregnant, breastfeeding, or planning to become pregnant during the trial or within one year of receiving the study treatment.
• People with any other condition that, in the treating doctor's judgement, would make participation unsafe, unsuitable, or interfere with the trial's assessments.

Important: Always verify eligibility with the trial site directly before applying.